Hepatic Macronodular Tuberculoma Mimics
Liver Metastasis in a Patient With
Locoregional Advanced Tongue Cancer
Case Report
A 55-year-old man had disseminated tuberculosis involving the lungs and right foot, with initial presentation of complicated right foot cellulitis. He had undergone antituberculosis treatment with com-bined use of pyrazinamide, rifampin, ethambutol, and isoniazid in April 2005. Other than the persistent abnormal appearance of plain chest radiographs, there were no clinical events thereafter. However, in September 2010, the patient presented with gradual dysphagia and odynophagia. On physical examination, an enlarged and indurated mass was noted on the left hemitongue. Several enlarged, painless, and fixed lymph nodes were palpable on the left upper neck region. Labo-ratory studies revealed normal blood counts, liver function tests, renal function, and inflammatory biomarkers. Incisional biopsy of the tongue mass confirmed the diagnosis of squamous cell carcinoma (SCC). Contrast-enhanced computed tomography (CT) of the head/ neck, chest, and upper abdomen for pretreatment evaluation revealed locally advanced tongue cancer (Fig 1A; arrow) and lymph node metastases in the left upper neck (Fig 1B; arrowhead). In addition, patchy consolidation with cystic, calcified, and fibronodular change was noted in the left lung (Fig 1C), compatible with pulmonary tuber-culosis also confirmed by the subsequent polymerase chain reaction assay for Mycobacterium tuberculosis complex from the patient’s spu-tum. Nevertheless, a hypodense nodule with minimal enhancement, measuring 16⫻ 12 mm, was found in segment four of the liver (Figs 2A, 2B; arrows).
For further differentiation of the hepatic lesion and whole-body survey of the tongue cancer, fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT was performed, revealing hyper-metabolic lesions suggestive of malignancy in the left tongue (Fig 2C;
maximum standardized uptake value [SUVmax], 13.2) and bilateral upper neck regions (Fig 2C; SUVmax, 3.2). Moreover, it also showed heterogeneous intense radioactivity (SUVmax, 2.8) in the left upper lung region (Fig 2C), compatible with an active inflammatory process such as pulmonary tuberculosis. Nevertheless, abnormal FDG uptake (SUVmax, 3.0) was also found in segment four of the liver (Figs 2C to 2E; arrowheads). Although the character of FDG uptake in the hepatic lesion might have been attributable to malignancy, an inflammatory process such as tuberculosis was also possible, because the lungs re-vealed probable active inflammation as with pulmonary tuberculosis. However, whether hepatic tuberculoma or hepatic metastasis from locoregional advanced tongue cancer, it was an unusual clinical man-ifestation. To determine a treatment strategy, it was necessary to ob-tain pathologic confirmation of the hepatic lesion.
Histologic examination of the hepatic nodule via CT-guided biopsy revealed caseating granulomatous inflammation characteristic of hepatic tuberculoma (Fig 3; hematoxylin and eosin stain,⫻200). As a result, this patient then underwent surgery for the tongue cancer and neck lymph node metastases, with the resulting pathologic stage of T4aN2cM0, stage IVA. Adjuvant chemoradiotherapy was initi-ated postoperatively.
Discussion
The incidence of distant metastases in patients with head and neck SCC (HNSCC) is relatively low in comparison with other malig-nancies.1
Approximately 15% to 30% of patients with HNSCC present with early-stage disease, and 60% to 80% present with locoregional advanced disease.2,3Distant metastasis at the time of presentation is less common, accounting for 2% to 17% of patients.1,4In postmortem studies, the overall prevalence of distant metastases in patients with HNSCC is higher and reported to be 10% to 60%.5Once distant metastases occur, prognosis is poor. Median time to death from diag-nosis of distant metastases ranges from 1 to 12 months.6
C
B
A
Fig 1.
J
OURNAL OF
C
LINICAL
O
NCOLOGY
D I A G N O S I S I N O N C O L O G Y© 2011 by American Society of Clinical Oncology 1 Journal of Clinical Oncology, Vol 29, 2011
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2011.34.9407
The latest version is at
Published Ahead of Print on May 23, 2011 as 10.1200/JCO.2011.34.9407
Copyright 2011 by American Society of Clinical Oncology 59.126.31.165
Information downloaded from jco.ascopubs.org and provided by at China Medical University on July 14, 2011 from Copyright © 2011 American Society of Clinical Oncology. All rights reserved.
The stage of the tumor, especially the presence and extension of lymph node metastases, greatly influences the incidence of distant metastases.1The presence of lymph node metastases increases the risk of developing distant metastases. A greater incidence of distant metas-tases is noted especially in patients with multiple or low jugular lymph node metastases.4The lungs (45% to 83%), bone (10% to 41%), and liver (6% to 24%) are the most common sites of distant metastases from HNSCC.5,7Therapy for patients with HNSCC and distant me-tastases is aimed at palliation, because cure rates at such an advanced stage are extremely low.2,8
On the other hand, hepatic tuberculosis is rare and constitutes less than 1% of all patient cases of tuberculosis.9,10Hepatic
tuberculo-sis has been classified by Levine11as miliary tuberculosis, pulmonary tuberculosis with hepatic involvement, primary liver tuberculosis, focal tuberculoma or abscess, or tuberculous cholangitis. Hepatic in-volvement as a part of miliary or pulmonary tuberculosis accounts for nearly 70% of patients,10and with hepatic tuberculosis, the initial lesion in the liver is a granulomatous tubercle, with or without caseat-ing necrosis, which may become fibrotic and calcified durcaseat-ing heal-ing.12Rarely, coalescent granulomas may form tuberculomas.9If the size of the hepatic nodules is greater than 2 mm, they are generally diagnosed as macronodular hepatic tuberculosis.13,14Imaging studies for hepatic tuberculosis are nonspecific and usually regarded as pri-mary or metastatic carcinoma.15,16Diagnosis often requires patho-logic confirmation via biopsy.17 Histologically, the presence of a caseating granuloma is diagnostic for hepatic tuberculosis.18Other diagnostic tests have low sensitivity, including acid-fast staining (0% to 45%), culture (10% to 60%), and even polymerase chain reaction (57%).11,19,20Quadruple therapy (isoniazid, rifampin, pyrazinamide, and ethambutol) is recommended because of the increasing incidence of drug-resistant tuberculosis. At least 1 year of medical therapy is generally required.10With early diagnosis and prompt effective treat-ment, the prognosis of hepatic tuberculosis is usually good.17On the contrary, untreated abdominal tuberculosis carries a 50% mortal-ity rate.21
The current patient case revealed an uncommon condition in-volving distinguishing two rare etiologies of a hepatic lesion in locore-gional advanced tongue cancer and pulmonary tuberculosis. Moreover, correct diagnosis was so important for this patient because both etiologies, if treated erroneously, might have caused unnecessary morbidity and even seriously accelerated mortality. In this case, both CT and FDG PET detected the hepatic lesion. In the absence of
B
A
D
E
C
Fig 2. Fig 3. Hsieh et al2 © 2011 by American Society of Clinical Oncology JOURNAL OFCLINICALONCOLOGY
59.126.31.165
Information downloaded from jco.ascopubs.org and provided by at China Medical University on July 14, 2011 from Copyright © 2011 American Society of Clinical Oncology. All rights reserved.
documented concurrent infection in the lungs, the patient may have been misdiagnosed with distant metastatic involvement of the liver and treated in a palliative fashion. As mentioned earlier, liver tubercu-losis, although rare, has been sporadically reported with or without pulmonary or miliary tuberculosis and is usually misrecognized as a primary or metastatic hepatic tumor. The diagnosis of hepatic tuber-culosis usually depends on pathologic confirmation. Therefore, once a patient with HNSCC presents with hepatic nodules, hepatic tuberculosis should be considered in the differential diagnosis, and pathologic confirmation may be necessary to direct subsequent appropriate treatment.
Te-Chun Hsieh and Yu-Chin Wu
China Medical University Hospital; and China Medical University, Taichung, Taiwan
Cheng-Nan Hsu, Chun-Fan Yang, I-Ping Chiang, and Ching-Yun Hsieh
China Medical University Hospital, Taichung, Taiwan
Shung-Shung Sun and Chia-Hung Kao
China Medical University Hospital; and China Medical University, Taichung, Taiwan
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST The author(s) indicated no potential conflicts of interest. REFERENCES
1. Brouwer J, Bree R, Hoekstra OS, et al: Screening for distant metastases in
patients with head and neck cancer: What is the current clinical practice? Clin Otolaryngol 30:438-443, 2005
2. Choong N, Vokes E: Expanding role of the medical oncologist in the
management of head and neck cancer. CA Cancer J Clin 58:32-53, 2008
3. Gourin CG, Watts TL, Williams HT, et al: Identification of distant
metasta-ses with positron-emission tomography-computed tomography in patients with previously untreated head and neck cancer. Laryngoscope 118:671-675, 2008
4. de Bree R, Deurloo EE, Snow GB, et al: Screening for distant metastases
in patients with head and neck cancer. Laryngoscope 110:397-401, 2000
5. Ferlito A, Shaha AR, Silver CE, et al: Incidence and sites of distant
metastases from head and neck cancer. ORL J Otorhinolaryngol Relat Spec 63:202-207, 2001
6. Calhoun KH, Fulmer P, Weiss R, et al: Distant metastases from head and
neck squamous cell carcinomas. Laryngoscope 104:1199-1205, 1994
7. Troell RJ, Terris DJ: Detection of metastases from head and neck cancers.
Laryngoscope 105:247-250, 1995
8. Senft A, de Bree R, Golding RP, et al: Interobserver variability in chest CT
and whole body FDG-PET screening for distant metastases in head and neck cancer patients. Mol Imaging Biol 13:385-390, 2011
9. Kok KY, Yapp SK: Isolated hepatic tuberculosis: Report of five cases and
review of the literature. J Hepatobiliary Pancreat Surg 6:195-198, 1999
10. Mert A, Ozaras R, Tabak F, et al: Localized hepatic tuberculosis. Eur
J Intern Med 14:511-512, 2003
11. Levine C: Primary macronodular hepatic tuberculosis: US and CT
appear-ances. Gastrointest Radiol 15:307-309, 1990
12. Kawamori Y, Matsui O, Kitagawa K, et al: Macronodular tuberculoma of the
liver: CT and MR findings. AJR Am J Roentgenol 158:311-313, 1992
13. Zipser RD, Rau JE, Ricketts RR, et al: Tuberculous pseudotumors of the
liver. Am J Med 61:946-951, 1976
14. Sarkar S, Saha K, Das CS: Isolated tuberculous liver abscess in a patient
with asymptomatic stage I sarcoidosis. Respir Care 55:1751-1753
15. Varela M, Ferna´ndez J, Navasa M, et al: Pseudotumoral hepatic
tubercu-losis. J Hepatol 39:654, 2003
16. Wang YT, Lu F, Zhu F, et al: Primary hepatic tuberculoma appears similar
to hepatic malignancy on F-18 FDG PET/CT. Clin Nucl Med 34:528-529, 2009
17. Tan TC, Cheung AY, Wan WY, et al: Tuberculoma of the liver presenting as
a hyperechoic mass on ultrasound. Br J Radiol 70:1293-1295, 1997
18. Alvarez SZ: Hepatobiliary tuberculosis. J Gastroenterol Hepatol
13:833-839, 1998
19. Huang WT, Wang CC, Chen WJ, et al: The nodular form of hepatic
tuberculosis: A review with five additional new cases. J Clin Pathol 56:835-839, 2003
20. Diaz ML, Herrera T, Lopez-Vidal Y, et al: Polymerase chain reaction for the
detection of Mycobacterium tuberculosis DNA in tissue and assessment of its utility in the diagnosis of hepatic granulomas. J Lab Clin Med 127:359-363, 1996
21. Hulnick DH, Megibow AJ, Naidich DP, et al: Abdominal tuberculosis: CT
evaluation. Radiology 157:199-204, 1985
DOI: 10.1200/JCO.2011.34.9407; published online ahead of print at www.jco.org on May 23, 2011
■ ■ ■ Diagnosis in Oncology
www.jco.org © 2011 by American Society of Clinical Oncology 3
59.126.31.165
Information downloaded from jco.ascopubs.org and provided by at China Medical University on July 14, 2011 from Copyright © 2011 American Society of Clinical Oncology. All rights reserved.